Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 348-10-7
2. 2-(2-fluorophenoxy)acetic Acid
3. (2-fluoro-phenoxy)-acetic Acid
4. Acetic Acid, (2-fluorophenoxy)-
5. Mfcd02223229
6. Enamine_002446
7. 2-(2-fluorophenoxy)acetic
8. Schembl257482
9. 2-(2-fluorophenoxy)aceticacid
10. (2-fluorophenyloxy)acetic Acid
11. (2-fluorophenoxy)acetic Acid #
12. Dtxsid80278826
13. [(2-fluorophenyl)oxy]acetic Acid
14. 2-(2-fluorophenoxy)-acetic Acid
15. Hms1400p04
16. Zinc262409
17. Albb-000256
18. Nsc10232
19. Bbl013906
20. Nsc-10232
21. Stk397466
22. (2-fluoro-phenoxy)-aceticacid
23. Akos000104348
24. (2-fluorophenoxy)acetic Acid, Aldrichcpr
25. As-10076
26. Sy008332
27. Db-069079
28. Bb 0217919
29. Cs-0072616
30. Ft-0678443
31. En300-00014
32. A874854
33. J-505621
34. F1791-0537
Molecular Weight | 170.14 g/mol |
---|---|
Molecular Formula | C8H7FO3 |
XLogP3 | 1.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 170.03792224 g/mol |
Monoisotopic Mass | 170.03792224 g/mol |
Topological Polar Surface Area | 46.5 Ų |
Heavy Atom Count | 12 |
Formal Charge | 0 |
Complexity | 160 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.
Lead Product(s): KMN-159,Collagen
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: NIDCR
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2021
Lead Product(s) : KMN-159,Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : NIDCR
Deal Size : $1.7 million
Deal Type : Funding
Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration
Details : The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2021
Details:
New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Lead Product(s): Hyaluronic Acid,Collagen,Dermatan Sulfate
Therapeutic Area: Dermatology Brand Name: Dermial
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2022
Lead Product(s) : Hyaluronic Acid,Collagen,Dermatan Sulfate
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Reveals Bioiberica's Dermial® Delivers Superior Benefits for Skin Health
Details : New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.
Product Name : Dermial
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2022
Details:
Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Skin Aging.
Lead Product(s): Collagen,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Chia Nan University of Pharmacy and Science
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2025
Lead Product(s) : Collagen,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Chia Nan University of Pharmacy and Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Skin-Beautifying Effects of Collagen Drinks
Details : Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Skin Aging.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 28, 2025
Details:
Biotin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alopecia.
Lead Product(s): Biotin,Collagen,Keratin,Hyaluronic Acid
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 20, 2024
Lead Product(s) : Biotin,Collagen,Keratin,Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Biotin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alopecia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 20, 2024
Details:
Hibiscus Sabdariffa Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Hibiscus Sabdariffa Extract,Collagen
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 14, 2023
Lead Product(s) : Hibiscus Sabdariffa Extract,Collagen
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Testing of Hibiscus Sabdariffa Extract and Collagen Products
Details : Hibiscus Sabdariffa Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 14, 2023
Details:
Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Collateral Ligament Injury of Stifle Joint.
Lead Product(s): Collagen,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2023
Lead Product(s) : Collagen,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Collateral Ligament Injury of Stifle Joint.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 02, 2023
Details:
Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Pain.
Lead Product(s): Collagen,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Tessenderlo Chemie NV
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 02, 2023
Lead Product(s) : Collagen,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Tessenderlo Chemie NV
Deal Size : Inapplicable
Deal Type : Inapplicable
Collagen Peptide Supplementation and Lifelong Athletes
Details : Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 02, 2023
Details:
Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Acne Vulgaris.
Lead Product(s): Collagen,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Collagen Lifesciences Private Limited
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2022
Lead Product(s) : Collagen,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Collagen Lifesciences Private Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Collagen is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 14, 2022
Details:
Whey Protein is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): Whey Protein,Collagen
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Sponsor: Rousselot BVBA
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 21, 2022
Lead Product(s) : Whey Protein,Collagen
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Rousselot BVBA
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Collagen Peptide Supplementation on Muscle and Tendon Damage and Function
Details : Whey Protein is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 21, 2022
Details:
Tac is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Skin Diseases.
Lead Product(s): Tac,Collagen
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Glac Biotech Co., Ltd
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2022
Lead Product(s) : Tac,Collagen
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Glac Biotech Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
A Project to Study Probiotic Beauty Products on Skin Improvement
Details : Tac is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Skin Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 11, 2022
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
25
PharmaCompass offers a list of Collagen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Collagen manufacturer or Collagen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Collagen manufacturer or Collagen supplier.
PharmaCompass also assists you with knowing the Collagen API Price utilized in the formulation of products. Collagen API Price is not always fixed or binding as the Collagen Price is obtained through a variety of data sources. The Collagen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Collagen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Collagen, including repackagers and relabelers. The FDA regulates Collagen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Collagen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Collagen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Collagen supplier is an individual or a company that provides Collagen active pharmaceutical ingredient (API) or Collagen finished formulations upon request. The Collagen suppliers may include Collagen API manufacturers, exporters, distributors and traders.
click here to find a list of Collagen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Collagen CEP of the European Pharmacopoeia monograph is often referred to as a Collagen Certificate of Suitability (COS). The purpose of a Collagen CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Collagen EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Collagen to their clients by showing that a Collagen CEP has been issued for it. The manufacturer submits a Collagen CEP (COS) as part of the market authorization procedure, and it takes on the role of a Collagen CEP holder for the record. Additionally, the data presented in the Collagen CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Collagen DMF.
A Collagen CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Collagen CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Collagen suppliers with CEP (COS) on PharmaCompass.
Collagen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Collagen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Collagen GMP manufacturer or Collagen GMP API supplier for your needs.
A Collagen CoA (Certificate of Analysis) is a formal document that attests to Collagen's compliance with Collagen specifications and serves as a tool for batch-level quality control.
Collagen CoA mostly includes findings from lab analyses of a specific batch. For each Collagen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Collagen may be tested according to a variety of international standards, such as European Pharmacopoeia (Collagen EP), Collagen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Collagen USP).